baudax bio inc shares were down 17 to 348 wednesday one day after the company said the first interim analysis of a phase 2 trial of its blocking agent bx1000 had a successful trial outcome the pennsylvaniabased biotechnology company said the trial which evaluated safety and tolerability found bx1000 treatments were generally well tolerated with no occurrence of severe or serious adverse events bx1000 treats neuromuscular blockade in patients undergoing elective surgery the stock closed tuesdays session up 32 and is down 99 over the past 12 months the company said it plans to complete enrollment in the bx1000 study in the first quarter and to share topline results for the study in april the primary efficacy endpoint of the bx1000 study which would enroll 80 adults is the proportion of patients who meet the criteria for good or excellent intubating conditions using a standardized scale baudax bio shares hit their 52week low of 155 on dec 19 and are down 97 over the past twelve months